Links are not yet activated.
To activate, add a link back to submitpr.org from your website and contact @jaycosta on Telegram,
or pay via Solana (from $19.95) for instant activation.
The weight loss drug market is about to change forever. On **April 10, 2026**, the FDA will decide whether to approve **orforglipron** — Eli Lilly's once-daily weight loss pill that could make weekly injections obsolete for millions of patients.If approved, orforglipron would be the first small-molecule oral GLP-1 drug for obesity, joining injectable heavyweights **Ozempic** (semaglutide) and **Mounjaro** (tirzepatide) in a market that generated $36.5 billion last year alone.
But which one is actually best for you? Here's how they compare on the numbers that matter.
| Feature | Orforglipron | Ozempic (Semaglutide) | Mounjaro (Tirzepatide) |
|---|---|---|---|
| **How you take it** | Daily pill | Weekly injection | Weekly injection |
| **Weight loss** | ~12.4% (72 weeks) | ~14.9% (68 weeks) | ~20.9–22.5% (72 weeks) |
| **A1C reduction** | 2.2% | 1.8% | 2.4% |
| **Fasting required?** | No | N/A (injection) | N/A (injection) |
| **Refrigeration needed?** | No | Yes | Yes |
| **FDA approved?** | Decision April 10, 2026 | Yes (2017) | Yes (2022) |
| **Estimated cost** | ~$200/month | ~$900/month (list) | ~$1,060/month (list) |
| **Manufacturer** | Eli Lilly | Novo Nordisk | Eli Lilly |
::stats
- **12.4%** — Orforglipron weight loss over 72 weeks
- **22.5%** — Mounjaro's maximum recorded weight loss
- **April 10** — FDA decision date for orforglipron
- **~$200/mo** — Expected orforglipron launch price
::end
## Why Orforglipron Changes Everything
The biggest advantage of orforglipron isn't the weight loss numbers — it's the form factor. Unlike Ozempic and Mounjaro, which require weekly self-injections with refrigerated pens, orforglipron is a **room-temperature daily pill** with no fasting restrictions.
That last point matters more than it sounds. Novo Nordisk already sells an oral semaglutide (Rybelsus), but it requires patients to take it on an empty stomach and wait 30 minutes before eating or drinking. In the landmark **ACHIEVE-3 trial** published in *The Lancet* in February 2026, orforglipron crushed Rybelsus head-to-head:
::versus
**Orforglipron (36 mg daily)**
- A1C reduction: 2.2%
- Weight loss: 19.7 lbs (9.2%)
- No food timing restrictions
- No refrigeration needed
vs
**Oral Semaglutide (Rybelsus, 14 mg daily)**
- A1C reduction: 1.4%
- Weight loss: 11.0 lbs (5.3%)
- 30-minute fasting window required
- Room temperature storage
::end
*"The differences were clinically meaningful. Orforglipron outperformed oral semaglutide on every key endpoint,"* said **Dr. Julio Rosenstock**, lead investigator and clinical professor at UT Southwestern.
For full coverage, visit https://www.linos.ai/health/orforglipron-vs-ozempic-vs-mounjaro-2026-weight-loss-pill-comparison/
About Linos NEWS: Linos NEWS (https://www.linos.ai) delivers breaking news and in-depth analysis across politics, technology, business, science, health, world affairs, sports, and entertainment.